Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy

Holly R. Keir, James D. Chalmers

Source: Eur Respir Rev, 31 (163) 210241; 10.1183/16000617.0241-2021
Journal Issue: March

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Holly R. Keir, James D. Chalmers. Neutrophil extracellular traps in chronic lung disease: implications for pathogenesis and therapy. Eur Respir Rev, 31 (163) 210241; 10.1183/16000617.0241-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Role of the inflammasome in the pathophysiology of antisynthetase-associated interstitial lung disease.
Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases
Year: 2021

Role of neutrophil mechanisms of inflammation in pathogenesis of different types of pulmonary fibrosis
Source: Eur Respir J 2003; 22: Suppl. 45, 459s
Year: 2003

Neutrophil extracellular traps (NETs) in COPD: A potential novel mechanism for host damage in acute exacerbations
Source: International Congress 2015 – Cellular and molecular mechanisms of COPD and emphysema
Year: 2015

Host–microbe cross-talk in the lung microenvironment: implications for understanding and treating chronic lung disease
Source: Eur Respir J, 56 (2) 1902320; 10.1183/13993003.02320-2019
Year: 2020

Erythromycin inhibits neutrophil extracellular traps in smoking-related chronic pulmonary inflammation
Source: International Congress 2019 – Advances in COPD pharmacology
Year: 2019

Pathogenesis of idiopathic pulmonary fibrosis: role of neutrophil inflammation
Source: Eur Respir J 2006; 28: Suppl. 50, 102s
Year: 2006

Prevalence and trafficking of circulating fibrocytes in smoking-related fibrogenic lung diseases
Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Year: 2015

Predictive role of neutrophil elastase in the follow-up of patients with interstitial lung diseases
Source: Eur Respir J 2001; 18: Suppl. 33, 409s
Year: 2001

A?-Val360: a marker of neutrophil elastase and COPD disease activity
Source: Eur Respir J 2013; 41: 31-38
Year: 2013

Cellular interactions in the pathogenesis of interstitial lung diseases
Source: Eur Respir Rev 2015; 24: 102-114
Year: 2015

Revisiting the role of pulmonary surfactant in chronic inflammatory lung diseases and environmental exposure
Source: Eur Respir Rev, 30 (162) 210077; 10.1183/16000617.0077-2021
Year: 2021

Neutrophil elastase in children with chronic lung diseases
Source: Annual Congress 2008 - Cystic fibrosis: a disease with many aspects
Year: 2008

Macrophage dysfunction in the pathogenesis and treatment of asthma
Source: Eur Respir J, 50 (3) 1700196; 10.1183/13993003.00196-2017
Year: 2017

Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease
Source: International Congress 2016 – ILD pathogenesis
Year: 2016

Sputum protein profiles for monitoring lung pathophysiology in chronic lung diseases
Source: Annual Congress 2012 - Recent progress in mechanisms and diagnostics of COPD and asthma
Year: 2012

Effects of a neutrophil elastase inhibitor against mediators of acute exacerbation of pulmonary fibrosis: a new therapeutic strategy
Source: Annual Congress 2008 - New therapeutic strategies in idiopathic pulmonary fibrosis
Year: 2008

Role of systemic inflammation mediated by IL-6 and TNF-alpha cytokines in chronic obstructive pulmonary disease and its progression: A three year follow up study
Source: Annual Congress 2013 –Systemic and airway biomarkers in respiratory diseases
Year: 2013

Neutrophil elastase levels is higher in patients with lung cancer than chronic obstructive pulmonary disease
Source: Annual Congress 2011 - Biomarkers and other new methods for lung cancer
Year: 2011

Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases
Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019
Year: 2019